Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines

Pharm Res. 2018 Nov 8;36(1):8. doi: 10.1007/s11095-018-2528-9.

Abstract

Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a deadly infectious disease. The thin pipeline of new drugs for TB, the ineffectiveness in adults of the only vaccine available, i.e. the Bacillus Calmette-Guerin vaccine, and increasing global antimicrobial resistance, has reinvigorated interest in immunotherapies. Nanoparticles (NPs) potentiate the effect of immune modulating compounds (IMC), enabling cell targeting, improved transfection of antigens, enhanced compound stability and provide opportunities for synergistic action, via delivery of multiple IMCs. In this review we describe work performed in the application of NPs towards achieving immune modulation for TB treatment and vaccination. Firstly, we present a comprehensive review of M. tuberculosis and how the bacterium modulates the host immune system. We find that current work suggest great promise of NP based immunotherapeutics as novel treatments and vaccination systems. There is need to intensify research efforts in this field, and rationally design novel NP immunotherapeutics based on current knowledge of the mycobacteriology and immune escape mechanisms employed by M. tuberculosis.

Keywords: Mycobacterium tuberculosis; immunotherapeutic nanoparticles; immunotherapy for tuberculosis; nanoparticle based host directed therapy; nanoparticles and vaccination.

Publication types

  • Review

MeSH terms

  • Animals
  • Host-Pathogen Interactions
  • Humans
  • Immune System* / immunology
  • Immune System* / microbiology
  • Immunotherapy
  • Mycobacterium tuberculosis* / immunology
  • Mycobacterium tuberculosis* / metabolism
  • Nanoparticles
  • Tuberculosis / microbiology
  • Tuberculosis / prevention & control
  • Vaccination